After a panicked Questcor (NASDAQ:QCOR) sell-off on Friday, the stock has stabilized. What was the cause for alarm? It turns out that Questcor's champion drug, Acthar -- which has an orphan designation from the Food and Drug Administration for the treatment of infantile spasms and is the major money-maker for Questcor -- may have a major new generic competitor from abroad poised to challenge its position. And the competition is a lot cheaper. Motley Fool health care bureau chief Brenton Flynn takes us through what this may mean for the company, why the alarm over this may all be just a storm in a teacup, and what to keep your eye on going forward.